Immune checkpoint inhibitors may heighten cardiovascular risks by altering immune interactions in atherosclerotic plaques, particularly in diabetic patients.
Immune checkpoint inhibitors may heighten cardiovascular risks by altering immune interactions in atherosclerotic plaques, particularly in diabetic patients.